Jul 30 |
Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
|
Jul 25 |
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
|
Jul 2 |
Inozyme gets Fast Track status for candidate for rare calcification condition
|
Jul 2 |
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
|
Jun 30 |
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?
|
Jun 21 |
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
|
May 30 |
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
|
May 23 |
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
|
May 8 |
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
|
May 8 |
Inozyme Pharma GAAP EPS of -$0.38 beats by $0.02
|